These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 7987821

  • 1. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
    Schmidt EE, Ichimura K, Reifenberger G, Collins VP.
    Cancer Res; 1994 Dec 15; 54(24):6321-4. PubMed ID: 7987821
    [Abstract] [Full Text] [Related]

  • 2. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN.
    Cancer Res; 1996 Jan 01; 56(1):150-3. PubMed ID: 8548755
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.
    Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M.
    Cancer Res; 1995 Jan 01; 55(1):20-3. PubMed ID: 7805033
    [Abstract] [Full Text] [Related]

  • 6. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p.
    Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN.
    Hum Mol Genet; 1994 Oct 01; 3(10):1841-5. PubMed ID: 7849711
    [Abstract] [Full Text] [Related]

  • 7. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B.
    Am J Pathol; 1995 Mar 01; 146(3):613-9. PubMed ID: 7887443
    [Abstract] [Full Text] [Related]

  • 8. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N.
    Neuro Oncol; 2007 Apr 01; 9(2):113-23. PubMed ID: 17327574
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
    Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J.
    Nat Genet; 1994 Sep 01; 8(1):23-6. PubMed ID: 7987388
    [Abstract] [Full Text] [Related]

  • 10. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.
    Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP.
    Cancer Res; 1994 Aug 15; 54(16):4299-303. PubMed ID: 8044775
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Deletion of p16 and p15 genes in brain tumors.
    Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B.
    Cancer Res; 1994 Dec 15; 54(24):6353-8. PubMed ID: 7987828
    [Abstract] [Full Text] [Related]

  • 14. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK.
    Cancer Res; 1997 Nov 01; 57(21):4868-75. PubMed ID: 9354451
    [Abstract] [Full Text] [Related]

  • 15. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W, Debiec-Rychter M, Liberski PP.
    Pol J Pathol; 1998 Nov 01; 49(4):267-71. PubMed ID: 10323080
    [Abstract] [Full Text] [Related]

  • 16. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
    Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
    Cancer Res; 1997 Jul 01; 57(13):2703-9. PubMed ID: 9205080
    [Abstract] [Full Text] [Related]

  • 17. Instability of microsatellites in human gliomas.
    Dams E, Van de Kelft EJ, Martin JJ, Verlooy J, Willems PJ.
    Cancer Res; 1995 Apr 01; 55(7):1547-9. PubMed ID: 7882363
    [Abstract] [Full Text] [Related]

  • 18. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow PJ.
    Mol Carcinog; 1996 Jan 01; 15(1):5-10. PubMed ID: 8561866
    [Abstract] [Full Text] [Related]

  • 19. Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas.
    Nakamura M, Ishida E, Shimada K, Nakase H, Sakaki T, Konishi N.
    Acta Neuropathol; 2005 Oct 01; 110(4):402-10. PubMed ID: 16155764
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.